对于乳腺癌相关淋巴水肿（BCRL），早期检测和干预显著降低了进展为持续性BCRL（pBCRL）的风险。我们旨在提供长期随访数据，评估使用生物阻抗谱技术（BIS）进行早期检测和在家干预对降低pBCRL的效果，以指导监测建议。总共分析了148名于2014年11月至2017年12月期间接受乳腺癌腋窝淋巴结清扫术（ALND）的女性患者。基线BIS测量和术后随访分别于术后3个月、1年双年复查1次，然后改为每年复查1次。当BIS升高时触发评估并开始在家干预，重新评估是否解决或持续为pBCRL。分析了高危因素和时间参数。平均随访时间为55个月，65例（44%）患者的BIS异常。其中54例（82%）通过在家干预达到了缓解。总体pBCRL发生率为8%。首次BIS异常的平均时间为11.7个月。早期乳腺癌患者中没有出现pBCRL（0/34），而仅有5例（20%）1期乳腺癌患者出现pBCRL。所有2期和3期乳腺癌患者（7/7）均出现了pBCRL。pBCRL与阳性淋巴结数量、阳性淋巴结比例、淋巴水肿分期以及BIS异常的复发有关（p < 0.05）。我们的研究表明，接受ALND并通过BIS早期检测出BCRL的患者，采取在家干预的pBCRL发生率为8%。高风险患者应在术后9个月开始定期随访，以便及早干预。©2023年。外科肿瘤学会。

Early detection and intervention for breast cancer-related lymphedema (BCRL) significantly decreases progression to persistent BCRL (pBCRL). We aimed to provide long-term follow-up on our early detection with bioimpedance spectroscopy (BIS) and early home intervention demonstrating reduced pBCRL to guide surveillance recommendations.In total, 148 female patients with breast cancer who had axillary lymph node dissection (ALND) from November 2014 to December 2017 were analyzed. Baseline BIS measurements and postoperative follow-up occurred every 3 months for 1 year, biannual for 1 year, and then annually. An elevated BIS triggered evaluation and initiation of at-home interventions with reassessment for resolution versus persistent BCRL (pBCRL). High-risk factors and timing were analyzed.Mean follow-up was 55 months, and 65 (44%) patients had an abnormal BIS. Of these, 54 (82%) resolved with home intervention. The overall pBCRL rate was 8%. Average time to first abnormal BIS was 11.7 months. None of the stage 0 patients (0/34) and only 5/25 (20%) of stage 1 patients had pBCRL. All of stage 2 and stage 3 patients (7/7) had pBCRL. pBCRL correlated with number of positive nodes, percentage of positive nodes, stage of lymphedema at diagnosis, and recurring abnormal BIS measurements (p < 0.05).We have shown that patients undergoing ALND with early BCRL identified by BIS who performed home interventions had an 8% pBCRL rate. Patients at high risk for pBCRL should have routine surveillance starting at 9 months postoperatively to identify an opportunity for early intervention.© 2023. Society of Surgical Oncology.